Product
CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
3 clinical trials
6 indications
Indication
Acute Lymphocytic LeukemiaIndication
lymphomaIndication
Non-HodgkinIndication
Diffuse Large B-Cell LymphomaIndication
Follicular LymphomaIndication
mantle cell lymphomaClinical trial
A Phase I Open, Single-arm Study of JWCAR029 (CD19-targeted Chimeric Antigen Receptor T Cells) for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2023-10-31
Clinical trial
A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Non-Hodgkins LymphomaStatus: Active (not recruiting), Estimated PCD: 2021-09-10
Clinical trial
A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Mantle Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-10-25